+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020

  • ID: 5229498
  • Drug Pipelines
  • November 2020
  • Region: Global
  • 95 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Arc Therapeutics Inc
  • Astex Pharmaceuticals Inc
  • Neosome Life Sciences LLC
  • Nuvation Bio Inc
  • Pfizer Inc
Summary

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 1, 2, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Immunology, Ear Nose Throat Disorders, Metabolic Disorders and Respiratory which include indications Breast Cancer, Coronavirus Disease 2019 (COVID-19), Lung Cancer, Metastatic Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Inflammation, Non-Small Cell Lung Cancer, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Gliosarcoma, Hearing Disorders, High-Grade Glioma, Laryngeal Cancer, Lymphoma, Mantle Cell Lymphoma, Metastatic Brain Tumor, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Pediatric Diffuse Intrinsic Pontine Glioma, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Small-Cell Lung Cancer, Thymic Carcinoma and Uterine Cancer.

The latest report Cyclin Dependent Kinase 2 - Pipeline Review, H2 2020, outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Arc Therapeutics Inc
  • Astex Pharmaceuticals Inc
  • Neosome Life Sciences LLC
  • Nuvation Bio Inc
  • Pfizer Inc
Introduction

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
  • Adastra Pharmaceuticals Inc
  • Apollo Therapeutics LLC
  • Arc Therapeutics Inc
  • Astex Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Neosome Life Sciences LLC
  • Nuvation Bio Inc
  • Pfizer Inc
  • Prous Institute for Biomedical Research SA
  • Rizen (Suzhou) Biosciences Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Tiziana Life Sciences Plc
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles

AT-7519 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CCT-68127 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ebvaciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
fadraciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
JRP-890 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
JS-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
JS-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
kenpaullone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
milciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NEOS-518 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NUV-422 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PF-07104091 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
sapacitabine + seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit CDK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
zotiraciclib citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 26, 2020: Cyclacel presents phase 1 clinical data showing safety, anti-tumor activity and good oral bioavailability of fadraciclib in patients with advanced solid tumors at the EORTC-NCI-AACR Symposium 2020
  • Oct 13, 2020: Nuvation Bio announces FDA acceptance of investigational new drug (IND) application for NUV-422 for treatment of patients with high-grade gliomas
  • Oct 06, 2020: ICR to study fadraciclib to treat paediatric neuroblastoma
  • Sep 21, 2020: Cyclacel announces Fadraciclib abstract selected for oral presentation in the Late Breaking and Best Proffered Paper session at the 32nd EORTC-NCI-AACR Symposium 2020
  • Aug 21, 2020: Tiziana granted a patent on the use of milciclib in combination with tyrosine kinase inhibitors for treatment of hepatocellular carcinoma and other cancers
  • Jul 13, 2020: Cyclacel’s clinical stage CDK2/9 inhibitor Fadraciclib targets key anti-apoptotic and oncogenic pathways in cancer
  • May 14, 2020: Tiziana Lifesciences announces online publication of two abstracts at the American Society of Clinical Oncology (ASCO) reporting clinical activity and safety of Milciclib in patients with advanced hepatocellular carcinoma
  • May 11, 2020: Tiziana Life Sciences announces publishing of two e-abstracts featuring its Miliciclib
  • Dec 09, 2019: Cyclacel’s CYC065 and Venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias
  • Nov 06, 2019: Cyclacel Pharmaceuticals announces multiple clinical abstracts on CYC065 selected for presentation at the ASH 2019 Annual Meeting
  • Sep 09, 2019: Cyclacel Pharmaceuticals announces first patient treated with oral CYC065 in a phase 1 study in patients with advanced solid tumors
  • Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
  • Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
  • Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
  • Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Adastra Pharmaceuticals Inc, H2 2020
  • Pipeline by Apollo Therapeutics LLC, H2 2020
  • Pipeline by Arc Therapeutics Inc, H2 2020
  • Pipeline by Astex Pharmaceuticals Inc, H2 2020
  • Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020
  • Pipeline by Neosome Life Sciences LLC, H2 2020
  • Pipeline by Nuvation Bio Inc, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Prous Institute for Biomedical Research SA, H2 2020
  • Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2020
  • Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
  • Pipeline by Tiziana Life Sciences Plc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
Note: Product cover images may vary from those shown
  • Adastra Pharmaceuticals Inc
  • Apollo Therapeutics LLC
  • Arc Therapeutics Inc
  • Astex Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Neosome Life Sciences LLC
  • Nuvation Bio Inc
  • Pfizer Inc
  • Prous Institute for Biomedical Research SA
  • Rizen (Suzhou) Biosciences Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
Adroll
adroll